Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy (NCT07095998)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (20 items).
Location: Beth Israel Deaconess Medical Center — Boston, Massachusetts
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria Cohort A:
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familial neuropathy;
- Any contraindication for treatment with cisplatin as determined by their primary oncologist;
- Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
- Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
- Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
- Patients not considered to be able to comply with the protocol. Inclusion Criteria Cohort B:
- Adults age ≥ 18 with a diagnosis of cis-PN.
- The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy. Exclusion Criteria Cohort B:
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.